Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator with some beta-adrenergic stimulating properties. It is thought to act directly on vascular smooth muscle to produce vasodilation and may also increase intracellular cyclic AMP.
## Primary Indications
* Peripheral vascular diseases (e.g., arteriosclerosis obliterans, Beurger's disease, Raynaud's disease) to improve intermittent claudication.
* Cerebral vascular insufficiency.
* *Off-label:* Tocolysis (prevention of premature labor).
## Adult Dosing
* **Peripheral vascular disease/Cerebral vascular insufficiency:** 10 mg to 20 mg orally every 3 to 4 times daily.
* **Tocolysis (off-label):** 10 mg to 20 mg orally every 4 to 6 hours.
## Pediatric Dosing
* No established pediatric dosing. Use in children is generally not recommended.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment. However, caution and close monitoring may be warranted in patients with severe impairment.
## Contraindications
* None absolute, but use with caution in patients with significant hypotension or tachycardia.
* Avoid use in patients with suspected glaucoma or in those who have recently experienced a myocardial infarction.
## Adverse Effects
* **Common:** Nausea, vomiting, gastrointestinal upset, dizziness, flushing, weakness, nervousness, rash.
* **Less Common:** Hypotension, tachycardia, palpitations, epigastric distress, drowsiness, blurred vision.
## Key Drug Interactions
* **Antihypertensives:** May potentiate the hypotensive effects.
* **Sympathomimetic agents:** May enhance cardiovascular effects (tachycardia, palpitations).
* **Other vasodilators:** Additive hypotensive effects.
## Monitoring
* Blood pressure and heart rate.
* Symptoms of peripheral vascular disease or cerebral vascular insufficiency.
* Signs of adverse effects.
## Clinical Pearls
* Isoxsuprine is not effective in patients with severe obliterative vascular disease where surgical intervention is indicated.
* Patient education should include the importance of reporting any dizziness, hypotension, or significant changes in heart rate.
* Efficacy in tocolysis is controversial and its use for this indication is off-label and should be carefully considered.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and indications may vary based on patient-specific factors and local protocols.*
